for Physicians
for Patients

Thematic Area:  

Hyperoxaluria

The following guidance document has been endorsed by the Workgroup following standardized quality evaluation:

Fig.: Glyoxylate metabolism in primary hyperoxaluria. [Groothoff, J.W., Metry, E., Deesker, L. et al. Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. Nat Rev Nephrol (2023).]
Fig.: Glyoxylate metabolism in primary hyperoxaluria. [Groothoff, J.W., Metry, E., Deesker, L. et al. Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. Nat Rev Nephrol (2023).]

Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope

Consensus Statement from ERKNet and OxalEurope provides recommendations for the management of primary hyperoxaluria.

Primary hyperoxaluria is an inherited disorder that results from the overproduction of endogenous oxalate, leading to recurrent kidney stones, nephrocalcinosis, kidney failure and life-threatening systemic disease. This Consensus Statement from ERKNet and OxalEurope provides recommendations for the management of primary hyperoxaluria, including consideration of conventional therapies, new therapies and recommendations for patient follow-up.

DOI: https://doi.org/10.1038/s41581-022-00661-1

PDF: Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope